Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension

Authors: Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, Bruno Caramelli, Fadi Charchar, Julio A. Chirinos, Jordana B. Cohen, Antoine Cremer, Gian Luca Di Tanna, Alexandre Duvignaud, Daniel Freilich, D. H. Frank Gommans, Abraham E. Gracia‐Ramos, Thomas A. Murray, Facundo Pelorosso, Neil R. Poulter, Michael A. Puskarich, Konstantinos D. Rizas, Rodolfo Rothlin, Markus P. Schlaich, Michael Schreinlecher, Ulrike Muscha Steckelings, Abhinav Sharma, George S. Stergiou, Christopher J. Tignanelli, Maciej Tomaszewski, Thomas Unger, Roland R. J. van Kimmenade, Richard D. Wainford, Bryan Williams, Anthony Rodgers, Aletta E. Schutte

Source: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 17 (2022)

Subject Terms: acute kidney injury, angiotensin II receptor blockers, angiotensin‐converting enzyme inhibitors, COVID‐19, hypertension, renin‐angiotensin system inhibitors, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2047-9980

Access URL: https://doaj.org/article/1f10e3a056824f04b0479f27b6c3925f